Journal
ADVANCES IN THERAPY
Volume 38, Issue 2, Pages 793-834Publisher
SPRINGER
DOI: 10.1007/s12325-020-01571-z
Keywords
Biomarkers; Clinical practice; Early detection; Primary care; Upper gastrointestinal cancers
Funding
- CanTest Collaborative - Cancer Research UK [C8640/A23385]
- Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4)
- NIHR Leeds In Vitro Diagnostic Co-operative (UK)
Ask authors/readers for more resources
Detecting upper GI cancers in primary care is difficult due to common and non-specific symptoms. This study aimed to identify validated biomarkers for evaluation in low-prevalence populations. 149 eligible studies were identified, involving 22,264 cancer cases and 49,474 controls, with most biomarkers still at an early stage of validation.
Introduction Detecting upper gastrointestinal (GI) cancers in primary care is challenging, as cancer symptoms are common, often non-specific, and most patients presenting with these symptoms will not have cancer. Substantial investment has been made to develop biomarkers for cancer detection, but few have reached routine clinical practice. We aimed to identify novel biomarkers for upper GI cancers which have been sufficiently validated to be ready for evaluation in low-prevalence populations. Methods We systematically searched MEDLINE, Embase, Emcare, and Web of Science for studies published in English from January 2000 to October 2019 (PROSPERO registration CRD42020165005). Reference lists of included studies were assessed. Studies had to report on second measures of diagnostic performance (beyond discovery phase) for biomarkers (single or in panels) used to detect pancreatic, oesophageal, gastric, and biliary tract cancers. We included all designs and excluded studies with less than 50 cases/controls. Data were extracted on types of biomarkers, populations and outcomes. Heterogeneity prevented pooling of outcomes. Results We identified 149 eligible studies, involving 22,264 cancer cases and 49,474 controls. A total of 431 biomarkers were identified (183 microRNAs and other RNAs, 79 autoantibodies and other immunological markers, 119 other proteins, 36 metabolic markers, 6 circulating tumour DNA and 8 other). Over half (n = 231) were reported in pancreatic cancer studies. Only 35 biomarkers had been investigated in at least two studies, with reported outcomes for that individual marker for the same tumour type. Apolipoproteins (apoAII-AT and apoAII-ATQ), and pepsinogens (PGI and PGII) were the most promising biomarkers for pancreatic and gastric cancer, respectively. Conclusion Most novel biomarkers for the early detection of upper GI cancers are still at an early stage of matureness. Further evidence is needed on biomarker performance in low-prevalence populations, in addition to implementation and health economic studies, before extensive adoption into clinical practice can be recommended.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available